两种混合前哨淋巴结示踪剂的比较:吲哚菁绿(ICG)-99mTc-纳米胶体与ICG-99mTc-纳米扫描胶体在核医学与外科视角下的对比
该回顾性研究纳入24例阴茎癌或头颈黑色素瘤患者,分别使用ICG-99mTc-纳米胶体(n=11)或ICG-99mTc-纳米扫描胶体(n=13)进行前哨淋巴结手术。两组示踪剂在淋巴结摄取、前哨淋巴结识别能力上相似,纳米扫描胶体组体外荧光强度较低且ICG堆叠程度更高,未报告示踪剂相关不良事件,作者认为纳米扫描胶体可安全用于前哨淋巴结手术。
要点
- ICG-99mTc-纳米扫描胶体与前哨淋巴结识别能力与ICG-99mTc-纳米胶体相似。
- 阴茎癌患者中纳米扫描胶体组淋巴显像检出前哨淋巴结数3个(IQR 3-4)vs 纳米胶体组2个(IQR 2-3),p=0.045。
- 纳米扫描胶体组体外总荧光强度较低,p=0.0054,与纳米扫描剂型中ICG堆叠程度更高一致。
核心结论
- 基于该回顾性分析,ICG-99mTc-纳米扫描胶体具有与ICG-99mTc-纳米胶体相似的前哨淋巴结识别能力,可安全用于前哨淋巴结手术。
研究设计与样本
- 回顾性分析纳入24例计划行前哨淋巴结手术的阴茎癌或头颈黑色素瘤患者。
- 初始组11例接受ICG-99mTc-纳米胶体直至该示踪剂不再可用,第二组13例接受ICG-99mTc-纳米扫描胶体。
主要发现
- 前哨淋巴结平均示踪剂摄取ICG-99mTc-纳米胶体组为2.2±4.3%ID,ICG-99mTc-纳米扫描胶体组为1.8±2.6%ID,p=0.68。
- 阴茎癌患者淋巴显像检出前哨淋巴结数ICG-99mTc-纳米扫描胶体组为3个(IQR 3-4),ICG-99mTc-纳米胶体组为2个(IQR 2-3),p=0.045;头颈患者未见差异。
- 体外(台面)测量切除前哨淋巴结总荧光强度ICG-99mTc-纳米胶体组为24*10^9任意单位(IQR 1.6*10^9-14*10^9),ICG-99mTc-纳米扫描胶体组为4.6*10^9任意单位(IQR 2.4*10^9-42*10^9),p=0.0054。
- 纳米扫描胶体组体外总荧光强度较低,与纳米扫描剂型中ICG堆叠程度更高一致。
- 未报告示踪剂相关不良事件。
关键数值与推荐
- 阴茎癌患者淋巴显像检出前哨淋巴结数ICG-99mTc-纳米扫描胶体组3个(IQR 3-4)vs ICG-99mTc-纳米胶体组2个(IQR 2-3),p=0.045。
- 前哨淋巴结平均示踪剂摄取ICG-99mTc-纳米胶体组2.2±4.3%ID vs ICG-99mTc-纳米扫描胶体组1.8±2.6%ID,p=0.68。
- 体外总荧光强度ICG-99mTc-纳米胶体组24*10^9任意单位(IQR 1.6*10^9-14*10^9)vs ICG-99mTc-纳米扫描胶体组4.6*10^9任意单位(IQR 2.4*10^9-42*10^9),p=0.0054。
临床怎么用
- 作者认为ICG-99mTc-纳米扫描胶体具有与ICG-99mTc-纳米胶体相似的前哨淋巴结识别能力,可安全用于前哨淋巴结手术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lymph node (LN) metastasis is a relevant predictor for survival in patients with a.o. penile cancer (PeCa), malignant melanoma. The sentinel node (SN) procedure comprises targeted resection of the first tumour-draining SNs. Here, the hybrid tracer indocyanine green (ICG)-99mTc-nanocolloid has been used for several years to combine optical and nuclear detection. Recently, the resource of the nanocolloid precursor stopped production and the precursor was replaced by a different but chemically comparable colloid, nanoscan. Our aim was to study the performance of ICG-99mTc-nanoscan compared to ICG-99mTc-nanocolloid from a nuclear and surgical perspective. METHODS: Twenty-four patients with either PeCa or head-and-neck (H&N) melanoma and scheduled for a SN procedure were included. The initial group (n = 11) received ICG-99mTc-nanocolloid until no longer available; the second group (n = 13) received ICG-99mTc-nanoscan. Tracer uptake was assessed on lymphoscintigraphy and single-photon emission (SPECT). Intraoperatively, SNs were identified using gamma tracing and fluorescence imaging. Ex vivo (back-table) measurements were conducted to quantify the fluorescence emissions. Chemical analysis was performed to compare the ICG assembly on both precursors. RESULTS: The mean tracer uptake in the SNs was similar for ICG-99mTc-nanocolloid (2.2 ± 4.3%ID) and ICG-99mTc-nanoscan (1.8 ± 2.6%ID; p = 0.68). 3 SNs (interquartile range (IQR) 3-4) were detected on lymphoscintigraphy in PeCa patients receiving ICG-99mTc-nanoscan compared to 2 SNs (IQR 2-3) in PeCa patients receiving ICG-99mTc-nanocolloid (p = 0.045), no differences were observed in H&N patients. Back-table measurements of resected SNs revealed a lower total fluorescence intensity in the ICG-99mTc-nanoscan group (24*109 arbitrary units (A.U) IQR 1.6*109-14*109 in the ICG-99mTc-nanocolloid group versus 4.6*109 A.U. IQR 2.4*109-42*109 in the ICG-99mTc-nanoscan group, p = 0.0054). This was consistent with a larger degree of "stacked" ICG observed in the nanoscan formulation. No tracer-related adverse events were reported. CONCLUSIONS: Based on this retrospective analysis, we can conclude that ICG-99mTc-nanoscan has similar capacity for SN identification as ICG-99mTc-nanocolloid and can safely be implemented in SN procedures.
引用
- Vreeburg MTA, Azargoshasb S, van Willigen D, et al. Comparison of two hybrid sentinel node tracers: indocyanine green (ICG)-99mTc-nanocolloid vs. ICG-99mTc-nanoscan from a nuclear medicine and surgical perspective. Eur J Nucl Med Mol Imaging. 2023. PMID: 36929210. doi:10.1007/s00259-023-06157-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。